Glaucoma
📧 Sign up to get email alerts when something new happens for Glaucoma.
Sign up freeTop drugs studied for this disease
-
FDA label_change · 2021-06-22FDA Approved: BRINZOLAMIDE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for brinzolamide by Sandoz Inc. to update the product labeling. The update may reflect changes to in…
-
FDA approval · 2021-06-09FDA Approved: BETOPTIC S — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental NDA for BETOPTIC S (betaxolol hydrochloride) by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt [Phase 3]
A Phase 3 therapeutic equivalence trial comparing generic brinzolamide to Azopt in glaucoma and ocular hypertension has completed with resul…
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt [Phase 1, Phase 2]
A phase 1/2 trial comparing generic brinzolamide to Azopt for glaucoma-related indications has completed with results posted in 2021.
-
FDA approval · 2021-05-21FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application from Micro Labs Limited for generic dorzolamide hydrochloride and timolol maleate ophthalmic solutio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-05-14FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Original Application (Aurobindo Pharma Limited)
FDA approved a new generic combination eye drop of dorzolamide hydrochloride and timolol maleate for lowering intraocular pressure in open-a…
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: Antisecretory Factor (AF) Effects on Intraocular-pressure [Phase 3]
Phase 3 clinical trial investigating Antisecretory Factor effects on intraocular pressure in glaucoma has been terminated.
-
FDA approval · 2021-05-04FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals' original application for a generic dorzolamide hydrochloride and timolol maleate ophthalmic solution u…
-
CLINICAL_TRIALS trial_result · 2021-05-03Clinical Trial Update: A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 [Phase 2]
Phase 2 clinical trial evaluating 24-hour intraocular pressure lowering and systemic exposure of PF-04217329 in glaucoma and ocular hyperten…
-
FDA approval · 2021-03-16FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for the fixed-dose combination dorzolamide hydrochloride and timolol maleate from Sandoz Inc.
-
FDA approval · 2021-02-22FDA Approved: ACETAZOLAMIDE — Original Application (TRUPHARMA, LLC)
The FDA approved an original ANDA for Acetazolamide, a generic version manufactured by TRUPHARMA, LLC.
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients [Phase 3]
Phase 3 trial evaluating latanoprost, timolol, and their combination for eye pressure reduction in open-angle glaucoma and ocular hypertensi…
-
CLINICAL_TRIALS trial_result · 2021-02-21Clinical Trial Update: Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh. [Phase 4]
Phase 4 trial evaluating the intraocular pressure lowering effect of Xalacom in patients with primary open-angle glaucoma or ocular hyperten…
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A Study of Glaucoma or Ocular Hypertension in Patients Within the United States [Phase 3]
Phase 3 clinical trial update for glaucoma or ocular hypertension sponsored by Pfizer/Mylan (Viatris) has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-18Clinical Trial Update: A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma [Phase 4]
A Phase 4 randomized trial comparing evening dosing of Xalacom versus Cosopt in glaucoma patients completed.
-
CLINICAL_TRIALS trial_result · 2021-02-08Clinical Trial Update: Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost [Phase 4]
Phase 4 trial comparing efficacy and ocular surface outcomes between Monoprost and BAK-preserved latanoprost in glaucoma and ocular hyperten…
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases [Phase 4]
Phase 4 trial investigating oral citicoline effects on neural conduction along visual pathways in patients with optic nerve diseases has com…
-
CLINICAL_TRIALS withdrawal · 2021-02-02Clinical Trial Update: Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device [Phase 3]
Phase 3 trial evaluating safety and efficacy of Xalatan delivered by a conventional dropper bottle versus a delivery device was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US [Phase 4]
A phase 4 trial comparing latanoprost with travoprost and bimatoprost in patients with elevated intraocular pressure, completed in the US.
-
CLINICAL_TRIALS trial_result · 2021-01-25Clinical Trial Update: Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS) [Phase 3]
Phase 3 clinical trial update for phosphodiesterase inhibitors in glaucoma has been suspended.
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study [Phase 4]
Phase 4 clinical trial update evaluating peripapillary blood flow after use of anti-glaucoma medications using OCT angiography.
-
CLINICAL_TRIALS trial_result · 2020-12-21Clinical Trial Update: Collision Warning Device for Blind and Visually Impaired [NA]
A completed clinical trial investigating a collision warning device for individuals with visual field impairments has posted results.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension [Phase 1, Phase 2]
A clinical trial update comparing RKI983 at 0.05% and 0.10% to Xalatan in patients with primary open-angle glaucoma or ocular hypertension; …
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol [Phase 4]
Phase 4 trial comparing 24-hour intraocular pressure effects of brinzolamide/timolol versus brimonidine/timolol in glaucoma.
-
CLINICAL_TRIALS trial_result · 2020-12-17Clinical Trial Update: 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy [Phase 4]
Phase 4 trial update on 24-hour efficacy and ocular surface effects of Talfuprost in combination therapy for glaucoma and ocular surface dis…